Urine Proteomics to Detect Biomarkers for Chronic Allograft Dysfunction
Authors:
- Lui[Combining Acute Accent]S F. QuintanaLQLui[Combining Acute Accent]S F. Quintana
- Amanda Sole[Combining Acute Accent]-GonzalezAAAmanda Sole[Combining Acute Accent]-Gonzalez
- Susana G. KalkoSKSusana G. Kalko
- Elisenda Ban[Combining Tilde]On-ManeusETElisenda Ban[Combining Tilde]On-Maneus
- Manel Sole[Combining Acute Accent]MAManel Sole[Combining Acute Accent]
- Fritz DiekmannFDFritz Diekmann
- Alex Gutierrez-DalmauAGAlex Gutierrez-Dalmau
- Joaquin AbianJAJoaquin Abian
- Josep M. CampistolJCJosep M. Campistol
- 1 February 2009
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 20 (2) , 428-435
Abstract
Despite optimal immunosuppressive therapy, more than 50% of kidney transplants fail because of chronic allograft dysfunction. A noninvasive means to diagnose chronic allograft dysfunction may allow earlier interventions that could improve graft half-life. In this proof-of-concept study, we used mass spectrometry to analyze differences in the urinary polypeptide patterns of 32 patients with chronic allograft dysfunction (14 with pure interstitial fibrosis and tubular atrophy and 18 with chronic active antibody-mediated rejection) and 18 control subjects (eight stable recipients and 10 healthy control subjects). Unsupervised hierarchical clustering showed good segregation of samples in groups corresponding mainly to the four biomedical conditions. Moreover, the composition of the proteome of the pure interstitial fibrosis and tubular atrophy group differed from that of the chronic active antibody-mediated rejection group, and an independent validation set confirmed these results. The 14 protein ions that best discriminated between these two groups correctly identified 100% of the patients with pure interstitial fibrosis and tubular atrophy and 100% of the patients with chronic active antibody-mediated rejection. In summary, this study establishes a pattern for two histologic lesions associated with distinct graft outcomes and constitutes a first step to designing a specific, noninvasive diagnostic tool for chronic allograft dysfunction.Keywords
This publication has 32 references indexed in Scilit:
- A 25-Signal Proteomic Signature and Outcome for Patients With Resected Non–Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2007
- Sample preparation and bioinformatics in MALDI profiling of urinary proteinsJournal of Chromatography B, 2007
- Banff ’05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (’CAN’)American Journal of Transplantation, 2007
- Organ Exchanges: Fairness to the O-Blood GroupAmerican Journal of Transplantation, 2006
- Longitudinal analysis of chronic allograft nephropathy: Clinicopathologic correlationsKidney International, 2005
- Patient Survival Following Renal Transplant Failure in CanadaAmerican Journal of Transplantation, 2005
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences, 2001
- Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric TransplantNew England Journal of Medicine, 1999
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- Early protocol renal allograft biopsies and graft outcomeKidney International, 1997